Press Releases

Berlin, April 2022 – The MEL Commission of the Austrian Ministry of Social Affairs has included the LiMAx® test in the MEL list 2022. In the new service catalog, the new group "APG07.02 - Special diagnostics - Gastrointestinal tract 2" was created. Under APG07.02 A, the new service "HL510 - Liver function test with application of a C13-labeled substrate (LE=per session)" is listed - the LiMAx® test, the use of which can be coded with 458 points in an outpatient setting.

The listing was based to a large extent on the results of the Mini Health Technology Assessment conducted in 2019 by the Competence Center for Medical Devices (CCMD). At the time, the institute confirmed the clinical and economic advantage of the LiMAx^® system for interventional use in liver surgery and highlighted the non-invasive breath test as particularly innovative.

With the help of the worldwide unique Liver Maximum Capacity Test (LiMAx^®), which quantifies the maximum functional capacity of the liver, physicians can specifically examine the liver for possible diseases. The results can be used to better plan interventions on the liver and thus minimize risks for patients.

Berlin, January 2020 – The consensus paper concludes that application of this novel breath test in the field of liver diagnostics improves patient care and generates economic advantages over existing methods.

Berlin, August 18, 2019 – Since a few years, the LiMAx liver function test has increasingly been utilized as a standard liver diagnostic test for non-invasive real-time assessment of metabolic liver function in numerous German, Austrian, and Swiss clinics.

Berlin, Germany, October 24, 2018 – Humedics GmbH, a specialist in real-time measurement of liver function capacity, announced results of a retrospective study that assessed the diagnostic accuracy of the LiMAx® test in patients with chronic liver disease. Results showed that the test can be a useful method to noninvasively determine hepatic disease severity.

Berlin, Germany, and Paris, France, April 12, 2018 – Humedics GmbH, a specialist in real-time measurement of individual liver function, today announced that the company has received Marketing Authorization for its diagnostic agent LiMAxetin® in two additional countries: Germany and Austria. LiMAxetin® is the diagnostic agent used to perform the LiMAx® test.

Berlin, Germany, May 09, 2017 – The Board of Humedics GmbH is pleased to announce a reinforcement of the senior team of the company with Karsten Damgaard-Iversen (MBA, BScEE), who will take up the role of CEO as of June 1, 2017. Erwin de Buijzer will stay on as managing director (MD) with the title Chief Operations Officer (COO).

Berlin, Germany, May 12, 2016 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that the company has submitted the marketing authorization application for the diagnostic agent necessary for the performance of the LiMAx test. The dossier was submitted in Germany, UK and Austria.

Berlin, Germany, September 1, 2015 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced results of a clinical study performed at the RWTH Aachen University Hospital. The aim of the study was to assess alterations in liver function capacity with the LiMAx test after bariatric surgery of obese patients. Study results demonstrated that fatty liver disease is reversible after weight reduction and that the LiMAx test is a reliable tool to measure functional liver recovery after obesity surgery.

Berlin, Germany, December 17, 2014 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that BioMedInvest-II LP complementary joins the Series C financing round now totaling more than 7 million Euro. Humedics’ business model, products and company development has attracted another international investor.

Berlin, Germany, February 28, 2013 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced the start of a clinical phase III trial. The main goal of this study is the early identification of low-risk patients after partial liver resection by the LiMAx test and improvements in patient management based on test results. After the initiation of first study centers in January, first patients already have been enrolled in Berlin and Jena.

Berlin, Germany, May 4, 2012 - Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that Erwin de Buijzer MD MBA has joined Humedics as managing director to support the further development and strategic positioning of the company.